Concepts (71)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Magnesium Deficiency | 1 | 2018 | 2 | 0.620 |
Why?
|
| Soybean Proteins | 1 | 2018 | 8 | 0.610 |
Why?
|
| Magnesium Oxide | 1 | 2018 | 8 | 0.610 |
Why?
|
| Kidney Transplantation | 1 | 2018 | 43 | 0.580 |
Why?
|
| Kidney Function Tests | 1 | 2016 | 19 | 0.540 |
Why?
|
| Glomerular Filtration Rate | 1 | 2016 | 48 | 0.530 |
Why?
|
| Overweight | 1 | 2016 | 110 | 0.500 |
Why?
|
| Postoperative Complications | 1 | 2018 | 604 | 0.430 |
Why?
|
| Enoxaparin | 1 | 2011 | 37 | 0.370 |
Why?
|
| Venous Thromboembolism | 1 | 2011 | 132 | 0.320 |
Why?
|
| Anticoagulants | 1 | 2011 | 293 | 0.310 |
Why?
|
| Pediatrics | 2 | 2019 | 87 | 0.300 |
Why?
|
| Colic | 1 | 2006 | 1 | 0.270 |
Why?
|
| Bismuth | 1 | 2006 | 2 | 0.270 |
Why?
|
| Salicylates | 1 | 2006 | 3 | 0.270 |
Why?
|
| Organometallic Compounds | 1 | 2006 | 40 | 0.260 |
Why?
|
| Child | 4 | 2018 | 2146 | 0.250 |
Why?
|
| Obesity | 1 | 2011 | 650 | 0.250 |
Why?
|
| Adolescent | 3 | 2018 | 2955 | 0.220 |
Why?
|
| Child, Preschool | 2 | 2018 | 1090 | 0.220 |
Why?
|
| Follow-Up Studies | 2 | 2018 | 980 | 0.200 |
Why?
|
| Curriculum | 2 | 2019 | 262 | 0.170 |
Why?
|
| Employment | 1 | 2019 | 45 | 0.170 |
Why?
|
| Career Choice | 1 | 2019 | 52 | 0.160 |
Why?
|
| Male | 5 | 2018 | 12868 | 0.160 |
Why?
|
| Magnesium | 1 | 2018 | 40 | 0.150 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 289 | 0.140 |
Why?
|
| Body Surface Area | 1 | 2016 | 7 | 0.140 |
Why?
|
| Creatinine | 1 | 2016 | 57 | 0.130 |
Why?
|
| Education, Pharmacy | 1 | 2018 | 104 | 0.130 |
Why?
|
| Humans | 8 | 2019 | 26828 | 0.130 |
Why?
|
| Biomarkers | 1 | 2018 | 733 | 0.120 |
Why?
|
| Case-Control Studies | 1 | 2016 | 702 | 0.120 |
Why?
|
| Drug Administration Schedule | 2 | 2011 | 218 | 0.110 |
Why?
|
| Prospective Studies | 1 | 2016 | 1216 | 0.100 |
Why?
|
| Female | 3 | 2018 | 14456 | 0.100 |
Why?
|
| Retrospective Studies | 2 | 2016 | 2429 | 0.100 |
Why?
|
| Treatment Outcome | 1 | 2018 | 2262 | 0.100 |
Why?
|
| Injections, Subcutaneous | 1 | 2011 | 58 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2011 | 586 | 0.080 |
Why?
|
| Receptors, Prostaglandin E | 1 | 2007 | 6 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2009 | 121 | 0.070 |
Why?
|
| Insulin | 1 | 2009 | 310 | 0.070 |
Why?
|
| Dinoprostone | 1 | 2007 | 41 | 0.070 |
Why?
|
| Polycystic Kidney, Autosomal Dominant | 1 | 2007 | 36 | 0.070 |
Why?
|
| Kidney | 1 | 2007 | 275 | 0.060 |
Why?
|
| Infant | 1 | 2006 | 957 | 0.050 |
Why?
|
| Education, Pharmacy, Graduate | 1 | 2019 | 17 | 0.040 |
Why?
|
| Self Efficacy | 1 | 2019 | 72 | 0.040 |
Why?
|
| Scholarly Communication | 1 | 2018 | 3 | 0.040 |
Why?
|
| Accreditation | 1 | 2018 | 33 | 0.040 |
Why?
|
| Program Development | 1 | 2018 | 74 | 0.040 |
Why?
|
| Surveys and Questionnaires | 1 | 2019 | 917 | 0.030 |
Why?
|
| Oklahoma | 1 | 2018 | 973 | 0.030 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2009 | 10 | 0.020 |
Why?
|
| Insurance, Health | 1 | 2009 | 51 | 0.020 |
Why?
|
| Medically Uninsured | 1 | 2009 | 30 | 0.020 |
Why?
|
| Glycated Hemoglobin A | 1 | 2009 | 64 | 0.020 |
Why?
|
| Medicaid | 1 | 2009 | 52 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2009 | 105 | 0.020 |
Why?
|
| Receptors, Prostaglandin E, EP2 Subtype | 1 | 2007 | 3 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2009 | 300 | 0.020 |
Why?
|
| Spheroids, Cellular | 1 | 2007 | 52 | 0.020 |
Why?
|
| Cyclic AMP | 1 | 2007 | 80 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2007 | 117 | 0.020 |
Why?
|
| Transfection | 1 | 2007 | 312 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2007 | 194 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2007 | 240 | 0.020 |
Why?
|
| Apoptosis | 1 | 2007 | 739 | 0.010 |
Why?
|
| United States | 1 | 2009 | 2031 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2007 | 1344 | 0.010 |
Why?
|